




PHARMACEUTICAL 2017

Zyla Life Sciences
Rank 228 of 292





PHARMACEUTICAL 2017

Zyla Life Sciences
Rank 228 of 292

The relative strengths and weaknesses of Zyla Life Sciences are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zyla Life Sciences compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Zyla Life Sciences is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is -73%, being 75% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	93,172
Cost of Goods Sold	0
Intangible Assets	8,350
Liabilities, Current	24,895
Liabilities, Non-Current	84,602
Other Assets	627
Other Compr. Net Income	141
Other Expenses	32,497
Other Liabilities	35
Other Net Income	-10,670
Other Revenues	16,964
Property and Equipment	12,709
Research and Development	33,759
Selling, General and Administrative Expense	30,670

Output Variable	Value in 1000 USD
Assets	114,858
Liabilities	109,532
Expenses	96,926
Revenues	16,964
Stockholders Equity	5,326
Net Income	-90,632
Comprehensive Net Income	-90,562
Economic Capital Ratio	-73%